Quick Links
Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


PER Pulse™ Recap
Medical Crossfire®: Mutational Testing through Multiple Lines of NSCLC Therapy reviews molecular testing in patients with lung cancer, deciding on frontline therapy for patients with epidermal growth factor receptor (EGFR) mutation-positive lung cancer, and managing acquired resistance to EGFR tyrosine kinase inhibitors. This activity features case vignettes and expert advice on patient management.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from AstraZeneca.

Medical Crossfire®: Mutational Testing Through Multiple Lines of NSCLC Therapy

Release Date: January 29, 2016
Expiration Date: January 29, 2017
Media: Internet - based

Activity Overview

This activity aims to update oncology healthcare professionals who participate in the multidisciplinary treatment of patients with lung cancers by providing expert guidance, interpretation, and opinions on the importance and impact of epidermal growth factor receptor (EGFR) and molecular testing through multiple lines of therapy and emerging technologies that can assist in this regard.

This will be a 3-module Medical Crossfire panel discussion, highlighting the expert exchange of ideas and best practices regarding the impact of mutational testing throughout the lung cancer treatment paradigm. Module 1 will include a discussion of needs in and ways to achieve optimal molecular testing. Modules 2 and 3 will be case-based discussions and interpretations in the setting of EGFR-mutated non–small cell lung cancer along the continuum of disease.

CME Activity Table of Contents

  • Module 1: Overview of Molecular Testing: Current and Future Directions
  • Module 2: The Front-Line Decision in EGFR Mutation-Positive Advanced NSCLC
  • Module 3: Beyond Disease Progression in the Patient Previously Treated With EGFR TKIs

Instructions For This Activity & Receiving Credit

  • You will need to login to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review videos/content until you finish the presentation.
  • At the end of the activity, "educational content/video" will be available for your reference.
  • In order to receive a CME certificate, participants must complete the activity.
  • Complete the posttest and pass with a score of 70% or higher, complete the evaluation and then click on request for credit. Participants may immediately download a CME certificate upon completion of these steps.

Target Audience

This educational activity is directed toward medical oncologists, pulmonologists, pathologists, and radiologists who treat patients with lung cancer. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals interested in the treatment of lung cancer may also participate.

Educational Objectives

At the conclusion of this activity, you should be better prepared to:
  • Describe evolving strategies to personalize treatment in patients with EGFR-mutated advanced non–small cell lung cancer (NSCLC)
  • Explain the importance of proper tissue acquisition to aid in the decision-making process in the context of identifying actionable mutations in lung cancer
  • Explain current and emerging technologies to monitor resistance and tumor heterogeneity in lung cancer, including evidence concerning the use of liquid biopsies to monitor resistance clones along the disease continuum
  • Apply a multidisciplinary approach to facilitate and optimize tumor tissue testing in the setting of advanced NSCLC and manage cases in multiple lines of care

Faculty, Staff, and Planners' Disclosures


Mark G. Kris, MD
Attending Physician, Thoracic Oncology Service
William and Joy Ruane Chair in Thoracic Oncology
Memorial Sloan Kettering Cancer Center
New York, NY

Benjamin P. Levy, MD
Assistant Professor, Icahn School of Medicine
Medical Director, Thoracic Oncology Program
Mount Sinai Health System
Associate Director, Cancer Clinical Trials Office
Mount Sinai Hospital
New York, NY

Gregory Riely, MD, PhD
Vice Chair, Clinical Trials Office
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, NY

Heather A. Wakelee, MD
Associate Professor, Medicine (Oncology)
Stanford University Medical Center
Stanford, CA


The following individuals have no relevant financial relationships with commercial interests to disclose:
The staff of Physicians’ Education Resource®, LLC.

The following individuals have relevant financial relationships with commercial interests to disclose:

Mark G. Kris, MD – Grant/Research Support: Puma Biotechnology, Pfizer, Genentech; Consultant: AstraZeneca, ARIAD Pharmaceuticals, Roche/Genentech, Array; Benjamin P. Levy, MD – Consultant: Genentech, Eli Lilly, AstraZeneca, Celgene Corporation, Biodesix; Speakers Bureau: Genentech; Gregory Riely, MD, PhD – Grant/Research Support: Roche, Novartis, Pfizer, Infinity, GlaxoSmithKline, Millennium: The Takeda Oncology Company; Consultant: Novartis; Heather Wakelee, MD – Grant/Research Support: Novartis, Bristol-Myers Squibb, Clovis Oncology, Xcovery, Celgene Corporation, Roche/Genentech, MedImmune, Pfizer, Lilly; Consultant: Peregrine Pharmaceuticals, Novartis, ACEA Biosciences

Disclosure Policy and Resolution of Conflicts of Interest (COI)

It is the policy of PER® to ensure the fair balance, independence, objectivity, and scientific objectivity in all of our CME activities. In accordance with ACCME guidelines, PER® requires everyone who is in a position to control the content of an educational activity, including spouses/partners, to disclose all relevant financial relationships with any commercial interest to participants as part of the activity planning process. PER® has implemented mechanisms to identify and resolve all conflicts of interest prior to release of this activity.

Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient's medical condition.

The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of Physicians' Education Resource®, LLC, or any of the companies that provided commercial support for this activity.

Hardware And Software Requirements

Supported Browsers
Internet Explorer v.7 or greater (for Windows) | Mozilla Firefox v.2 or greater (for Windows, Mac, Linux)

Minimum System Requirements (Windows)
  • A Pentium-based PC or compatible computer
  • At least 64MB of RAM
  • Windows 95/98/NT/ME/2000/XP/Vista system software
  • Screen resolution of 1024 x 786 or larger recommended
  • PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise
Minimum System Requirements (Mac OS)
  • A PowerPC processor-based Macintosh computer
  • At least 64MB of RAM
  • Mac OS 7.5 or later
  • Screen resolution of 1024 x 786 or larger recommended
  • PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise

Become a Member

Forgot Password?
Calendar of Events
Filter By